A
Alcista
Alcista · 25%MIST
$2.13
Precio del escenario
$0.693
-0.072 (-10.36%)Al cierre
Loading chart…
- Máximo
- 0.785
- Apertura
- 0.761
- Precio medio ponderado por volumen
- 0.72
- Volumen
- 1.19M
- Capitalización
- 68.71M
- Mínimo
- 0.675
- Importe
- 856.11K
- EV/EBITDA, TTM
- -0.08
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
Análisis de IA of Milestone Pharmaceuticals Inc (MIST)
ComprarMilestone Pharmaceuticals Inc is a good buy right now due to its recent approval for etripamil in China, which triggered a $2 million milestone payment and opens up a significant market opportunity. The current price is $0.7268, and analysts project a price target of $3, suggesting a potential upside of approximately 313%. Additionally, the stock has shown a 5-day change of +12.79%, indicating positive momentum. However, the main risk is the company's substantial net losses, with a net income of -$28,614,000 in Q2 2026.
Métricas de valoración
El PER previsto actual de Milestone Pharmaceuticals Inc (MIST) es 0.00, frente a su media de 5 años de -2.72.
Escenarios de precio de Alphio AI para MIST
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
5.011-04NewsfilterMilestone Pharmaceuticals Grants 33,000 Stock Options to New Employee
9.009-27NASDAQ.COMMilestone Pharmaceuticals Initiates Phase 3 Trial for Etripamil
9.009-03NASDAQ.COMMilestone Pharmaceuticals Secures Approval for Etripamil in China
- 8.509-03Newsfilter
Everest Medicines to Lead Etripamil Commercialization in Greater China
9.008-21NASDAQ.COMMilestone Pharmaceuticals Initiates Pivotal Phase 3 Trial for Etripamil in AFib-RVR
Preguntas frecuentes sobre MIST, respondidas por Alphio AI
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Milestone Pharmaceuticals Inc is a good buy right now due to its recent approval for etripamil in China, which triggered a $2 million milestone payment and opens up a significant market opportunity. The current price is $0.7268, and analysts project a price target of $3, suggesting a potential upside of approximately 313%. Additionally, the stock has shown a 5-day change of +12.79%, indicating positive momentum. However, the main risk is the company's substantial net losses, with a net income of -$28,614,000 in Q2 2026.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarArtículos relacionados
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.